From new journal publications and model system advancements to expanded availability, we're thrilled to share some major updates about Nanostics’ ClarityDX platform!
Earlier this year, Nanostics’ development and validation of the ClarityDX platform was detailed in the Nature Digital Medicine journal. For a deeper dive into their research, visit: Nature Digital Medicine Article.
Their manuscript, available as a preprint from The Lancet SSRN and currently in peer review with a leading digital health journal, details the evolution of ClarityDX into a more versatile 4-model system. Originally, the platform used a combination of total PSA and free PSA levels, along with three clinical features—age, prior negative biopsies, and digital rectal exam (DRE*) results—integrated with our machine learning algorithm.
Based on feedback from physicians, primary healthcare providers, and urologists, they have introduced three new models (1 simpler model and 2 advanced models) to improve utility and accuracy:
This advancement has been well-received by both patients and healthcare providers, reflecting its practical benefits and enhanced diagnostic precision.
ClarityDX Prostate is now accessible across five provinces in Canada (AB, BC, SK, ON, PQ) and one territory (Yukon), as well as in Florida, as of late August. This expansion provides opportunities to serve more patients and providers through their innovative platform.
Learn more about Nanostics’ ClarityDX platform here
**AUC: Area Under the Curve is used as a quantitative measurement of accuracy.
